Platelet activating factor: The good and the bad in the ischemic/reperfused heart

Experimental Biology and Medicine

Volumn 236, Issue 4, 2011, Pages 390-401

  Penna, Claudia ^a,b   Bassino, Eleonora ^c   Alloatti, Giuseppe ^b,c  

^a ASO San Luigi   (Italy)

^b Istituto Nazionale per la Ricerca Cardiovascolare (INRC)   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Heart; Ischemia reperfusion; Ischemic preconditioning; Platelet activating factor

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CALCIUM CHANNEL L TYPE; G PROTEIN COUPLED RECEPTOR; GLYCEROPHOSPHOLIPID; INTRACELLULAR CALCIUM SENSING PROTEIN; NITRIC OXIDE SYNTHASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN KINASE C; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

AUTOCRINE EFFECT; CALCIUM CELL LEVEL; CARDIOVASCULAR SYSTEM; CONCENTRATION (PARAMETERS); CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; DRUG MECHANISM; ELECTROPHYSIOLOGY; ENZYME PHOSPHORYLATION; HEART CONDUCTION; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INOTROPISM; ISCHEMIC PRECONDITIONING; LOW DRUG DOSE; NITROSYLATION; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN SECRETION; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; BIOSYNTHESIS; PHYSIOLOGY;

HUMANS; ISCHEMIC PRECONDITIONING; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PLATELET ACTIVATING FACTOR;

EID: 79958788029     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.010316     Document Type: Review

References (132)

1. Benveniste J, Henson PM, Cochrane CH. Leukocyte-dependent histamine release from rabbits platelets. The role of IgE, basophils, and a platelet activating factor. J Exp Med 1972;136:1356-1377
2. Kravis TC, Henson PM. IgE-induced release of a platelet activating factor from rabbit lung. J Immunol 1975;115:1677-1681
3. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993;292:617-629
4. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000;80:1669-1699
5. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000;69:419-445
6. Stafforini DM, Mcintyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003;40:643-672
7. Kasperska-Zaiac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov 2008;2:72-76
8. Kester M, Ledvora RF, Barany M. The potentiation of arterial contraction with platelet activating factor. Pflü gers Arch 1984;400:200-202
9. Benveniste J, Boullet C, Brink C, Labat C. The actions of PAF-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol 1983;80:81-83
10. Camussi G, Alloatti G, Montrucchio G, Meda M, Emanuelli G. Effect ofplatelet activating factor on guinea-pig papillary muscle. Experientia 1984;40:697-699
11. Levi R, Burke JA, Guo ZG, Hattori Y, Hoppens CM, McManus LM, Hanahan DDJ, Pinkard RN. Acetyl glyceryl ether phosphorylcholine (AGEPC), a putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res 1984;54:117-124
12. Alloatti G, Montrucchio G, Mariano F, Tetta C, De Paulis R, Morea M, Emanuelli G, Camussi G. Effect of platelet-activating factor (PAF) on human cardiac muscle. Int Arch Allergy Appl Immunol 1986;79:108-112
13. Robertson DA, Genovese A, Levi R. Negative inotropic effect on platelet-activating factor on human myocardium: a pharmacological study. J Pharmacol Exp Ther 1987;243:834-839
14. Robertson DA, Wang DY, Lee CO, Levi R. Negative inotropic effect of platelet-activating factor: association with a decrease in intracellular sodium activity. J Pharmacol Exp Ther 1988;245:124-128
15. Alonso F, Gill MG, Sanchez-Crespo M, Mato JM. Activation of 1-alkyl-2-lyso-glycero-3-phosphocholine-acetyl-CoA transferase during phagocytosis in human polymorphonuclear leukocytes. J Biol Chem 1982;257:3376-3378
16. Lee TC, Lenihan DJ, Malone B, Roddy LL, Wasserman SI. Increased biosynthesis of platelet activating factor in activated human eosinophils. J Biol Chem 1984;259:5526-5530
17. Ninio E, Mencia-Huerta JM, Heymans F, Benveniste J. Biosynthesis of platelet activating factor. 1. Evidence for a acetyl-transferase activity in murine macrophages. Biochim Biophys Acta 1982;710:23-31
18. Bussolino F, Gremo F, Tetta C, Pescarmona GP, Camussi G. Production of platelet activating factor by chick retina. J Biol Chem 1986;261:16502-16508
19. Snyder F. Enzymatic pathways for platelet activating factor, related alkyl glycerolipids and their precursors. In: Snyder F, ed. Platelet-Activating Factor and Related Lipid Mediators. Chapter 7. New York: Plenum, 1987
20. Farr RS, Cox CP, Wardlow ML, Jorgensen R. Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). Clin Immunol Immunopathol 1980;15:318-330
21. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009;23:73-83
22. Hwang SB, Ching-Shin CL, Cheah MJ, Shen TY. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. Biochemistry 1983;22:4756-4763
23. Sugimoto T, Tsuchinochi H, McGregor CG, Mutoh H, Shimizu T, Kurachi DY. Molecular cloning and characterization of the platelet activating factor receptor gene expressed in the human heart. Biochem Biophys Res Commun 1992;189:617-624
24. Korth R, Hirafuji M, Lalau-Keraly C, Delautier I, Bidault J, Benveniste J. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogue with human platelets and endothelial cells. Biochem Pharmacol 1989;44:223-229
25. Ihida K, Predescu D, Czekay RP, Palade GE. Platelet activating factor receptor is found in a large endosomal compartment in human umbilical vein endothelial cells. J Cell Sci 1999;112:285-295
26. Marrache AM, Gobeil F, Zhu T, Chemtob S. Intracellular signaling of lipid mediators via cognate nuclear G protein-coupled receptors. Endothelium 2005;12:63-72
27. Bito H, Shmizu T. Molecular characterization and physiological functions of PAF receptors. Adv Exp Med Biol 1997;400:215-221
28. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem 2002;131:773-779
29. Piper PJ, Stewart AG. Coronary vasoconstriction in the rat isolated perfused heart induced by platelet activating factor is mediated by leukotriene C4. Br J Pharmacol 1986;88:595-605
30. McIntyre TM, Reinhold SL, Prescott SM, Zimmerman GA. Protein kinase C activity appears to be required for the synthesis of platelet-activating factor and leukotriene B4 by human neutrophils. J Biol Chem 1987;262:15370-15376
31. O'Flaherty JT, Nishihira J. Arachidonate metabolites, platelet activating factor, and the mobilization of protein kinase C in human polymorphonuclear neutrophils. J Immunol 1987;138:1889-1895
32. Nakajima T, Sugimoto T, Kurachi Y. Platelet activating factor activates cardiac GK via arachidonic acid metabolites. FEBS Lett 1991;289:239-243
33. Piper PJ, Stewart AJ. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor antagonists. Br J Pharmacol 1987;90:771-783
34. Dhar A, Paul AK, Shukla SD. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: studies with genistein and monoclonal antibody phosphotyrosine. Mol Pharmacol 1990;37:519-525
35. Gomez-Cambronero J, Wang J, Johnson G, Huang CK, Sha'afi RI. Platelet activating factor induces tyrosine phosphorylation in human neutrophils. J Biol Chem 1991;266:6240-6245
36. Chao J, Liu H, Hanahan DJ, Olson MS. Platelet activating factor-stimulated protein tyrosine phosphorylation and eicosanoid synthesis in rat Kupffer cells. Evidence for calcium-dependent and protein-kinase C-dependent and C-independent pathways. J Biol Chem 1992;267:6725-6735
37. Shimizu T, Mori M, Bito H, Sakanaka C, Tabuchi S, Aihara M, Kume K. Platelet-activating factor and somatostatin activate mitogen-activated protein kinase (MAP kinase) and arachidonate release. J Lipid Mediat Cell Signal 1996;14:103-108
38. FAK) in human endothelial cells. Oncogene 1996;13:515-525
39. Nick JA, Avdi NJ, Young SK, Knall C, Gerwins P, Johnson GL, Worthen GS. Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet-activating factor and FMLP. J Clin Invest 1997;99:975-986
40. Stangl V, Baumann G, Stangl K, Felix SB. Negative inotropic mediators released from the heart after myocardial ischemia-reperfusion. Cardiovasc Res 2002;53:12-30
41. Piper HM, Meuter K, Schäfer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 2003;75:644-648
42. Hoffman JW Jr, Gilbert TB, Poston RS, Silldorff EP. Myocardial reperfusion injury: etiology, mechanisms and therapies. J Extra Corpor Technol 2004;36:391-411
43. Montrucchio G, Camussi G, Tetta C, Emanuelli G, Orzan F, Libero L, Brusca A. Intravascular release of platelet-activating factor during atrial pacing. Lancet 1986;8501:293
44. Stephens CJ, Graham RM, Sturm MJ, Richardson M, Taylor RR. Variation in plasma platelet-acivating factor degradation and serum lipids after acute myocardial infarction. Coron Artery Dis 1993;4:187-193
45. Graham RM, Strahan ME, Norman KW, Watkins DN, Sturm MJ, Taylor RR. Platelet and plasma platelet-activating factor in sepsis and myocardial infarction. J Lipid Mediat Cell Signal 1994;9:167-182
46. Montrucchio G, Bergerone S, Bussolino F, Alloatti G, Silvestro L, Lupia E, Cavetto A, Di Leo M, Emanuelli G, Camusi G. Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. Circulation 1993;88:1476-1483
47. Annable CR, McManus LM, Carey KD, Pinckard RN. Isolation of platelet-activating factor (PAF) from ischemic baboon myocardium (Abstract). Fed Proc 1985;44:1271
48. Ko W, Hawes AS, Douglas Lazenby W, Calvano SE, Shin YT, Zelano JA, Antonacci AC, Wayne Isom O, Krieger KH. Myocardial reperfusion injury: platelet activating factor stimulates polymorphonuclear leukocyte hydrogen peroxide production during myocardial reperfusion. J Thorac Cardiovasc Surg 1991;102:297-308
49. Leong LLL, Taylor R. The lyso-precursor of platelet-activating factor (lyso-PAF) in ischemic myocardium. J Lipid Mediat 1991;4:277-287
50. Montrucchio G, Alloatti G, Tetta C, De Luca R, Saunders RN, Emanuelli G, Camussi G. Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol Heart Circ Physiol 1989;256:1236-1246
51. Berti F, Magni F, Rossoni G, De Angelis L, Galli G. Production and biologic interactions of prostacyclin and platelet activating factor in acute myocardial ischemia in the perfused rabbit heart. J Cardiovasc Pharmacol 1990;16:727-732
52. Arnould T, Michiels C, Remacle J. Increased PMN adherence on endothelial cells after hypoxia: involvement of PAF, CD 18/CD 11b, and ICAM-1. Am J Physiol Cell Physiol 1993;264:1102-1110
53. Burghardt C, Janero DR. The anoxic rat-heart myocyte produces and release platelet-activating factor (PAF) as a component of its ischemia-like pathology. J Mol Cell Cardiol 1987;19 (Suppl. IV):pS69
54. Alloatti G, Montrucchio G, Emanuelli G, Camussi G. Platelet-activating factor induced platelet/neutrophil co-operation during myocardial reperfusion. J Moll Cell Cardiol 1992;24:163-171
55. Chakrabarty S, Fluck DS, Flores NA, Sheridan DJ. Effects of the PAF antagonist BN 50726 and BN 50739 on arrhythmogenesis and extent of necrosis during myocardial ischemia/reperfusion in rabbits. Br J Pharmacol 1992;107:705-709
56. Katoh S, Toyama J, Kodama I, Koike A, Abe T. Role of platelet activating factor in ischemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309. Cardiovasc Res 1993;27:1430-1434
57. Flores NA, Sheridan DJ. Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischemia and reperfusion in the guinea-pig. Br J Pharmacol 1990;101:734-738
58. Koltay M, Tosaki A, Hosford D, Esanu A, Braquet P. Effect of BN 50739, a new platelet activating factor antagonist, on ischemia induced ventricular arrhythmias in isolated working rat hearts. Cardiol Res 1991;25:391-397
59. Montrucchio G, Alloatti G, Mariano F, De Paulis R, Comino A, Emanuelli G, Camussi G. Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol 1990;137:71-83
60. Montrucchio G, Alloatti G, Mariano F, Comino A, Cacace G, Polloni R, De Filippi PG, Emanuelli G, Camussi G. Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart. Am J Pathol 1993;142:471-480
61. Ko W, Lang D, Hawes AS, Zelano JA, Isom OW, Krieger KH. Platelet activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion. J Surg Res 1993;55:504-515
62. Fontaliran F, Guillon JM, Koltai M, Braquet P. Reduction of infarct size by ginkgolide B (BN 52021) in coronary artery ligated rats. In: Braquet P, ed. Ginkgolides Chemistry, Biology, Pharmacology and Clinical Perspectives, Barcelona. Chapter 2. Barcelona: Prous Science, 1989
63. Ma XL, Weyrich AS, Krantz S, Lefer AM. Mechanisms of the cardioprotective actions of WEB 2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion. J Pharmacol Exp Ther 1992;260:1229-1236
64. Man RY, Kinnaird AA. Similar coronary vascular effects in the rat perfused heart of platelet activating factor structural analogues with agonist and antagonist properties. Br J Pharmacol 1995;116:2359-2364
65. Gross GJ, Maruyama M, Vercellotti GM, Jacob HS, Christensen CW. Effect of the PAF antagonist, BN 52021, on myocardial infarct size in dogs. In: Braquet P, ed. Ginkgolides Chemistry, Biology, Pharmacology and Clinical Perspectives. Barcelona: Prous Science, 1989;2:421-425
66. Tamura K, Kimura Y, Tamura T, Kitashiro S, Tzuoka T, Tsuji H, Twasaka T, Inada M. The effect of platelet activating factor antagonist TCV-309 on arrhythmias and functional recovery during myocardial reperfusion. Coronary Artery Dis 1994;5:267-273
67. Feuerstein G, Boyd LM, Ezra D, Goldstein RE. Effect of platelet-activating factor on coronary circulation of the domestic pig. Am J Physiol Heart Circ Physiol 1984;246:466-471
68. Montrucchio G, Alloatti G, Mariano F, Meda E, Tetta C, Emanuelli G, Camussi G. The pattern of cardiovascular alterations induced by infusion of platelet activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. Agents Actions 1987;21:72-78
69. Sybertz EJ, Watkins RW, Baum T, Pula K, Rivelli M. Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphorylcholine in the anesthetized dog. J Pharmacol Exp Ther 1985;232:156-162
70. Jackson CV, Schumacher WA, Kunkel SL, Driscoll EM, Lucchesi BR. Platelet activating factor and the release of platelet-derived coronary artery vasodilator substance in the canine. Circ Res 1986;58:218-229
71. Metha J, Wargovich T, Nichols W. Biphasic effects of platelet-activating factor on coronary blood flow in anesthetized dog. Prostaglandins Leukotrienes Med 1986;21:87-95
72. Kim YD, Danchak RM, Heim KF, Lees DE, Myers AK. Constriction of canine coronary arteries by platelet activating factor after brief ischemia. Prostaglandins 1993;46:69-76
73. Goldstein RE, Ezra D, Laurindo FRM, Feuerstein GZ. Coronary and pulmonary vascular effects of leukotrienes and PAF-acether. Pharmacol Res Commun 1986;18:151-162
74. Stahl GL, Lefer DJ, Lefer AM. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig-heart. Naunyn-Schmiedeberg's Arch Pharmacol 1987;336:459-463
75. Viossat I, Chapelat M, Chabrier PE, Braquet P. Effects of platelet-activating factor (PAF) and its receptor antagonist BN 52021 on isolated perfused guinea-pig heart. Prostaglandins Leukotrienes Essent Fatty Acids 1989;38:189-194
76. Stahl GL, Lefer AM. Mechanism of platelet-activating factor-induced cardiac depression in the isolated perfused rat heart. Circ Shock 1987;23:165-177
77. Hu W, Choy PC, Man RY. Characterization of the coronary vascular responses to platelet-activating factor in the isolated perfused heart. Lipids 1991;26:700-704
78. Hu W, Kinnaird AAA, Man RYK. Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart. Br J Pharmacol 1991;103:1097-1102
79. Kenzora JL, Perez JE, Bergmann SR, Lange LG. Effects of acetyl glyceryl ether phosphorylcholine (platelet activating factor) on ventricular preload, afterload and contractility in dogs. J Clin Invest 1984;74:1193-1203
80. Mickelson JK, Simpson PJ, Lucchesi BR. Myocardial dysfunction and coronary vasoconstriction induced by platelet-activating factor in the post-infarcted rabbit isolated heart. J Mol Cell Cardiol 1988;20:547-561
81. Tippins JR, Antoniw JW, Alison MR, Garvey B, Maseri A. WEB 2086 inhibits neutrophil dependent increases in coronary resistance in blood perfused rabbit heart. Cardiovasc Res 1992;26:162-169
82. Huang Q, Wu M, Meininger C, Kelly K, Yuan Y. Neutrophil-dependent augmentation of PAF-induced vasoconstriction and albumin flux in coronary arterioles. Am J Physiol Heart Circ Physiol 1998;275:1138-1147
83. Soloviev AE, Braquet P. The role of PAF-acether in the mechanism of isolated coronary artery spasm under hypoxia and its inhibition by BN 52021. In: Braquet P, ed. Ginkgolides Chemistry, Biology, Pharmacology and Clinical, Barcelona. Chapter 2. Barcelona: Prous Science, 1990
84. Goldstein RE, Feuerstein GZ, Bradley LM, Stambouly JJ, Laurindo FRM, Davenport NJ. Cardiovascular effects of platelet activating factor. Lipids 1991;26:1250-1256
85. Alloatti G, Montrucchio G, Mariano F, Tetta C, Emanuelli G, Camussi G. Protective effect of verapamil on the cardiac and circulatory alterations induced by platelet-activating factor. J Cardiovasc Pharmacol 1987;9:181-186
86. Riedel A, Mest HJ. The effect of PAF (platelet-activating factor) on experimental cardiac arrhythmias and its inhibition by substances influencing arachidonic acid metabolites. Adv Prostaglandins Leukotrienes Med 1987;28:103-109
87. Cervoni P, Herzlinger HE, Lai FM, Tanikella TK. Aortic vascular and atrial response to 1-O-octadecyl-2-acetyl-glyceryl-3-phosphocholine. Br J Pharmacol 1983;79:667-671
88. Diez J, Delpon E, Tamargo J. Effects of platelet activating factor on contractile force and Ca fluxes in guinea-pig isolated atria. Br J Pharmacol 1990;100:305-311
89. Tamargo J, Tejerina T, Delgado C, Barrigon S. Electrophysological effects of platelet-activating factor (PAF-acether) in guinea pig-papillary muscles. Eur J Pharmacol 1985;109:219-227
90. Pietsch P, Hunger T, Braun M, Roediger A, Baumann G, Felix SB. Effect of platelet-activating factor on intracellular Ca2{thorn} concentration and contractility in isolated cardiomyocytes. J Cardiovasc Pharmacol 1998;31:758-763
91. Gollasch M, Ignatieva V, Kobrinsky E, Vornovitsky E, Zaborovskaya L. Electrophysiological mechanisms responsible for the action of PAF in guinea-pig myocardium. Relation to the putative membrane signaling processes of PAF. J Lipid Mediat 1991;3:139-145
92. Wahler GM, Coyle DE, Sperelakis N. Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes. Mol Cell Biochem 1990;93:69-76
93. Besana A, Barbuti A, Tateyama MA, Symes AJ, Robinson RB, Feinmark SJ. Activation of protein kinase C epsilon inhibits the two-pore domain K+ channel, TASK-1, inducing repolarization abnormalities in cardiac ventricular myocytes. J Biol Chem 2004;279:33154-33160
94. Alloatti G, Levi R, Malan D, Del Sorbo L, Bosco O, Barberis L, Marcantoni A, Bedendi I, Penna C, Azzolino O, Altruda F, Wymann M, Hirsch E, Montrucchio G. phosphoinisitide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc Res 2003;60:242-249
95. Alloatti G, Penna C, De Martino A, Montrucchio G, Camussi G. Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-alpha in the guinea-pig papillary muscle. Cardiovasc Res 1999;41:611-619
96. Alloatti G, Penna C, Mariano F, Camussi G. Role of NO and PAF in the impairment of skeletal muscle contractility induced by TNF-alpha. Am J Physiol Regul Integr Comp Physiol 2000;279:2156-2163
97. 2+-dependent manner. Int J Cardiol 2010;143:86-93
98. Zhao ZQ. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol 2004;4:159-165
99. Alloatti G, Montrucchio G, Camussi G. Role of platelet-activating factor (PAF) in oxygen radical-induced cardiac dysfunction. J Pharmacol Exp Ther 1994;269:766-767
100. Lewis MS, Whatley RE, Cain P, McIntyre TM, Prescott TM, Zimmerman GA. Hydrogen peroxide stimulates the synthesis of platelet activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. J Clin Invest 1988;82:2045-2055
101. Lehr HA, Seemuller J, Hubner C, Menger MD, Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet activating factor. Arterioscl Thromb 1993;13:1013-1018
102. Miyaura S, Eguchi H, Johnston M. Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid platelet activating factor. Circ Res 1992;70:341-347
103. Rouis M, Nigon F, Chapman MJ. Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. Biochem Biophys Res Commun 1988;56:1293-1298
104. Tokumura A, Toujima M, Yoshioka Y, Fukuzawa K. Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids. Lipids 1996;31:1251-1258
105. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136
106. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. Am J Physiol 1986;251:1306-1315
107. Dekker LR. Toward the heart of ischemic peconditioning. Cardiovasc Res 1998;37:14-20
108. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007;116:173-191
109. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 2004;63:305-312
110. Leucor S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, Opie LH. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005;112:3911-3918
111. Cappello S, Angelone T, Tota B, Pagliaro P, Penna C, Rastaldo R, Corti A, Losano G, Cerra MC. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol 2007;293:719-727
112. Granata R, Trovato L, Gallo MP, Destefanis S, Settanni F, Scarlatti F, Brero A, Ramella R, Volante M, Isgaard J, Levi R, Papotti M, Alloatti G, Ghigo E. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischemia-reperfusion injury in rat heart. Cardiovasc Res 2009;83:303-312
113. Alloatti G, Arnoletti E, Bassino E, Penna C, Perrelli MG, Ghé C, Muccioli G. Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 2010;299:470-481
114. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009;104:1240-1252
115. Darius H, Lefer DJ, Smith JB, Lefer AM. Role of platelet activating factor-acether in mediating guinea pig anaphylaxis. Science 1986;232:58-60
116. Bozlu G, Atici A, Turhan AH, Polat A, Nayci A, Okuyaz C, Taskinlar H. Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Brain Res 2007;1143:193-198
117. Ryan SD, Harris CS, Mo F, Lee H, Hou ST, Bazan NG, Haddad PS, Arnason JT, Bennet SA. Platelet activating factor-induced neuronal apoptosis is initiated independently of its G-protein coupled PAF receptor and is inhibited by the benzoate orsellinic acid. J Neurochem 2007;103:88-97
118. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996;79:363-380
119. Penna C, Alloatti G, Cappello S, Gattullo D, Berta G, Mognetti B, Losano G, Pagliaro P. Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol 2005;288:2512-2520
120. Leary PJ, Rajasekaran S, Morrison RR, Tuomanen EI, Chin TK, Hofmann PA. A cardioprotective role for platelet activating factor through NOS dependent S-nitrosylation. Am J Physiol Heart Circ Physiol 2008;294:2775-2784
121. Penna C, Mognetti B, Tullio F, Gattullo D, Mancardi D, Moro F, Pagliaro P, Alloatti G. Post-ischemic activation of kinases in the pre-conditioning-like cardioprotective effect of the platelet-activating factor. Acta Physiol 2009;197:175-185
122. Penna C, Mognetti B, Tullio F, Gattullo D, Mancardi D, Pagliaro P, Alloatti G. The platelet activating factor triggers preconditioning-like cardioprotective effect via mitochondrial K-ATP channels and redox-sensible signaling. J Physiol Pharmacol 2008;59:47-54
123. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res 2008;77:334-343
124. 2+ channel a1 subunit and reduced ischemia/reperfusion injury. Circ Res 2006;98:403-411
125. Speechly-Dick ME, Grover GJ, Yellon DM. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995;77:1030-1035
126. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW Jr, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty clinical, hemodynamic, and metabolic features. Circulation 1990;82:2044-2051
127. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999;99:2085-2089
128. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993;342:276-277
129. Crisafulli A, Melis F, Tocco F, Santoboni UM, Lai C, Angioy G, Lorrai L, Pittau G, Concu A, Pagliaro P. Exercise-induced and nitroglycerininduced myocardial preconditioning improves hemodynamics in patients with angina. Am J Physiol Heart Circ Physiol 2004;287:235-242
130. Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS. Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol 2003;41:1174-1182
131. Michaelides AP, Andrikopoulos GK, Oikonomou EV, Psomadaki ZD, Richter DJ, Dilaveris PE, Exadaktylos NI, Stefanadis CI, Toutouzas PK. Improved myocardial performance during repetitive exercise testing: the role of extracellular superoxide dismutase activity in a model of exercise-induced myocardial preconditioning. Am Heart J 2003;146:160-167
132. Cavallo-Perin P, Lupia E, Gruden G, Olivetti C, De Martino A, Cassader M, Furlani D, Servillo L, Quagliuolo L, Iorio E, Boccellino MR, Montrucchio G, Camussi G. Increased blood levels of platelet activating factor in insulin-dependent diabetic patients with microalbuminuria. Nephrol Dial Transpl 2000;15:994-999